NO20073755L - Ibandronatpolymorf B - Google Patents

Ibandronatpolymorf B

Info

Publication number
NO20073755L
NO20073755L NO20073755A NO20073755A NO20073755L NO 20073755 L NO20073755 L NO 20073755L NO 20073755 A NO20073755 A NO 20073755A NO 20073755 A NO20073755 A NO 20073755A NO 20073755 L NO20073755 L NO 20073755L
Authority
NO
Norway
Prior art keywords
ibandronate
ibandronate polymorph
polymorph
hydroxypropane
pentyl
Prior art date
Application number
NO20073755A
Other languages
English (en)
Inventor
Uwe Eiermann
Bernd Junghans
Bernhard Knipp
Tim Sattelkau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36088250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073755(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073755L publication Critical patent/NO20073755L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

Foreliggende oppfinnelse angår en ny krystallinsk polymorf av 3-(N-metyl-N-pentyl) amino-1-hydroksypropan-1,1-difosfonsyre mononatriumsalt monohydrat (Ibandronat) med den følgende formel Formel 1
NO20073755A 2005-02-01 2007-07-19 Ibandronatpolymorf B NO20073755L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100687 2005-02-01
PCT/EP2006/000579 WO2006081962A1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph b

Publications (1)

Publication Number Publication Date
NO20073755L true NO20073755L (no) 2007-08-28

Family

ID=36088250

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073755A NO20073755L (no) 2005-02-01 2007-07-19 Ibandronatpolymorf B

Country Status (20)

Country Link
US (2) US7582789B2 (no)
EP (3) EP1848727B1 (no)
JP (2) JP5828607B2 (no)
KR (1) KR100908530B1 (no)
CN (1) CN101111505B (no)
AR (1) AR053119A1 (no)
AU (1) AU2006210008B2 (no)
BR (1) BRPI0607093A2 (no)
CA (1) CA2594717C (no)
DK (1) DK1848727T3 (no)
ES (1) ES2543804T3 (no)
IL (1) IL184720A (no)
MX (1) MX2007008917A (no)
NO (1) NO20073755L (no)
PL (1) PL1848727T3 (no)
RU (1) RU2387661C2 (no)
SI (1) SI1848727T1 (no)
TW (1) TWI374888B (no)
WO (1) WO2006081962A1 (no)
ZA (1) ZA200706170B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1713489E (pt) 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
SI1848727T1 (sl) 2005-02-01 2015-09-30 F. Hoffmann-La Roche Ag Polimorf b ibandronata
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
PT103600B (pt) * 2006-11-06 2009-01-30 Hovione Farmaciencia Sa Processo para a preparação de ácidos biosfónicos e seus sais farmaceuticamente aceitáveis
EP2009016A3 (en) * 2006-11-16 2009-02-25 Teva Pharmaceutical Industries Ltd Process for preparing crystalline form of ibandronate sodium
PL2144919T3 (pl) * 2007-04-11 2016-05-31 Hoffmann La Roche Wieloetapowa synteza ibandronianu
KR20100014728A (ko) * 2007-04-19 2010-02-10 닥터 레디스 레보러터리즈 리미티드 이반드로네이트 나트륨 다형태
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
ES2428699T3 (es) * 2007-10-26 2013-11-08 Chemo Ibérica, S.A. Formas polimórficas de ibandronato de sodio y procedimientos para la preparación del mismo
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) * 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764604A (en) * 1968-12-17 1973-10-09 Us Army 4-pyridylcarbinolamine anti-malarials
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (no) * 1988-11-28 1993-01-11 Ciba Geigy Ag
MA22668A1 (fr) * 1990-07-10 1993-07-01 Smithkline Beecham Corp Procede de preparation d'oxamides .
DE19531264A1 (de) * 1995-08-25 1997-02-27 Hoechst Ag Kationische, ungesättigte Saccharide sowie daraus hergestellte Polymerisate und deren Verwendung
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
DE69907495T2 (de) 1998-10-16 2004-05-06 Akzo Nobel N.V. (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on als reine verbindung
ATE303153T1 (de) * 1998-12-04 2005-09-15 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
WO2001075080A1 (en) * 2000-03-30 2001-10-11 Research Development Foundation Tyr393 and tyr398 mutants of monoamine oxidase b
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
PT1713489E (pt) * 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
WO2006081963A1 (en) * 2005-02-01 2006-08-10 F.Hoffmann-La Roche Ag Ibandronate polymorph a
SI1848727T1 (sl) 2005-02-01 2015-09-30 F. Hoffmann-La Roche Ag Polimorf b ibandronata

Also Published As

Publication number Publication date
TWI374888B (en) 2012-10-21
US20090312289A1 (en) 2009-12-17
KR100908530B1 (ko) 2009-07-20
CA2594717C (en) 2015-01-20
EP1848727B1 (en) 2015-06-17
ES2543804T3 (es) 2015-08-24
IL184720A0 (en) 2007-12-03
US7582789B2 (en) 2009-09-01
JP2008531480A (ja) 2008-08-14
RU2387661C2 (ru) 2010-04-27
CN101111505B (zh) 2011-09-14
JP2015205908A (ja) 2015-11-19
CA2594717A1 (en) 2006-08-10
AU2006210008B2 (en) 2009-10-08
JP5828607B2 (ja) 2015-12-09
ZA200706170B (en) 2008-09-25
IL184720A (en) 2014-12-31
TW200640940A (en) 2006-12-01
JP6039755B2 (ja) 2016-12-07
CN101111505A (zh) 2008-01-23
PL1848727T3 (pl) 2015-11-30
BRPI0607093A2 (pt) 2009-08-04
EP2610261A1 (en) 2013-07-03
EP2363401A1 (en) 2011-09-07
AR053119A1 (es) 2007-04-25
MX2007008917A (es) 2007-08-21
AU2006210008A1 (en) 2006-08-10
KR20070100395A (ko) 2007-10-10
US20060172976A1 (en) 2006-08-03
DK1848727T3 (da) 2015-07-20
SI1848727T1 (sl) 2015-09-30
EP1848727A1 (en) 2007-10-31
RU2007132700A (ru) 2009-03-10
WO2006081962A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
NO20073755L (no) Ibandronatpolymorf B
NO20073723L (no) Ibandronatpolymorf A
IL182690A0 (en) Process for the preparation of ibandronate
IL172513A0 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
NO20076597L (no) Fremgangsmater for fremstilling av 4-(bifenylyl)azetidin-2-one fosforsyrer
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
EA200970569A1 (ru) Применимые в качестве гербицидных соединений пиридопиразиновые производные
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
NO20054669L (no) Substituerte kinobenzoxazinanaloger
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
WO2007074475A3 (en) Novel polymorphic forms of ibandronate
MX359363B (es) Dihidroetorfina y su preparacion.
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
ZA200800138B (en) Process for the preparation of crystalline perindopril
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
MX2009010850A (es) Sintesis de ibandronato en multiples etapas.
NO20055755L (no) Nytt intermediat for fremstillingen av terapeutisk aktive imidazopyridiner
NO20091971L (no) Saltformer av substituerte benzotienylforbindelser
TW200801016A (en) Thienopyridine-2-carboxamide derivatives
TH96053A (th) เกลือไฮโดรเจนซัลเฟตชนิดใหม่
WO2010084507A3 (en) Process for the preparation of n-methyl-2-[3-(1-methyl-4-piperidyl)-1h-indol-5-yl]-ethanesulfonamide and its acid addition salts
TH85269B (th) อิแบนโดรเนตพอลิมอร์ฟ a
RS51372B (en) TRIAZOLOPIRAZINE UNITS USEFUL FOR TREATMENT OF DEGENERATIVE INFLAMMATORY DISEASES
TH115418B (th) ไดไฮโดรเอเทอร์ฟีนและการเตรียมไดไฮโดรเอทอร์ฟีนเหล่านี้

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ATNAHS PHARMA UK LIMITED, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application